Within AML, nine proteins had a pattern in which levels were higher in the pediatric subgroups (ages <2, 2–10, 10–18 years), with two proteins (RAD51, WEE1) dropping in a linear fashion across all age groups and the other six progressively declining in the 18–29, 30–59 and 60+ subgroups starting after age 18 (CHEK2, CHEK2-pThr68, MSH2, RPA32, RPA32-pSer4_8, and XRCC1). This evidence concerns the gene CHEK2 and acute myeloid leukemia.